Menu
A Generic infrastructure for developing tools for early, accurate and accessible diagnosis of human diseases.
In today’s global healthcare landscape, there’s a pressing demand for technologies that allow for a much earlier diagnosis, when diseases can be cured, which, in turn also reduces treatment costs while relieving pressure on health systems.
However, the main obstacle to achieving this goal is developing technologies that are sensitive, precise, and readily available.
To help Israeli companies create sensitive, accurate, and accessible sensing technologies, there is a significant need to institutionalize generic technology that enables the identification of biological multi-omics markers and integrate them into modular and easily accessible sensing products for point of care diagnosis. Doing so will speed up the development of innovative products for early detection and revolutionize the healthcare industry.
Israel has a wealth of technological pioneers in both industry and academia who are working on groundbreaking technologies. By harnessing their collective potential in the LIQUIDBX consortium, we create the infrastructure to establish global leaders in this field.
Current State of the Art in liquid Biopsy.
The current state of liquid biopsy technology is primarily focused on sensitive cancer detection for early diagnosis and residual disease monitoring. The major players in the field are primarily concentrating their efforts on a single measurement, mainly genomics or DNA methylation-based technologies. Diagnosis is largely based on markers derived from the tumor itself, and most efforts are geared towards complex and relatively costly technologies that require laboratory services
A. Multi-Omics platform for early pre-symptomatic detection of disease markers.
LIQUIDBX consortium is developing an infrastructure for the development of a generic technological toolbox for the detection of biological markers and their integration into modular generic sensors for the early detection of diseases. The multi-omic sensors will identify signals coming from multiple biological elements including genomics, epigenomics, metabolomics, proteomics, the immune system and more.
The consortium aims to enhance the accuracy and precision of state-of-the-art Israeli liquid biopsy technologies by integrating information from diverse measurement sources through advanced computational methods. Additionally, the consortium strives to create sensor technologies that are sensitive, specific, modular, and easily accessible to facilitate early diagnosis.
B. LIQUIDBX Innovative and generic tool-box – a fast and efficient route from identifying multi omics biomarkers
to point of care diagnostic products for the Israeli industry
Protocols and procedures for effective handling of various body fluids. Optimized analysis with methods for maximizing the information obtained from a minimal volume of body fluids. Protocols for generating data from various single omics technologies
Methods for identifying biomarkers from intricate multi-omics data Creation of advanced computational tools that can learn across different technologies and handle incomplete data in a flexible way. A framework that acquires general rules rather than disease-specific ones. Cloud-based instruments for data input and biomarker generation. A "Plug and Play" system that allows for the insertion of any multi-omics dataset and the acquisition of an optimal set of biomarkers for detection through sensors.
Novel sensors capable of detecting multiple types of biomolecules concurrently. The advancement of technology to merge various sensors into a single product in a versatile and modular fashion The establishment of a universal solution for point-of-care biomolecule sensing regardless of any specific disease involved.
C. A multi-Omics Sensors platform for Point of Care diagnostics
In the consortium we develop a generic platform that will enable multi-omics sensing for point of care. The Platform includes a modular “lego-like” integration of various sensing devices which will be developed by consortium members and integrated together with a supportive fusion analytics software.
Copyright 2023 LIQUIDBX – All Rights Reserved
Produced by Webzilla